DrugPatentWatch Database Preview
Investigational Drug Information for Tegafur
Email this page to a colleague
What is the development status for investigational drug Tegafur?
Tegafur is an investigational drug.
There have been 140 clinical trials for Tegafur.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Colorectal Neoplasms. The leading clinical trial sponsors are Fudan University, National Taiwan University Hospital, and Taiho Pharmaceutical Co., Ltd.
There is one US patent protecting this investigational drug and twenty-seven international patents.
Summary for Tegafur
| US Patents | 1,778 |
| International Patents | 27,409 |
| US Patent Applications | 4,257 |
| WIPO Patent Applications | 2,623 |
| Japanese Patent Applications | 250 |
| Clinical Trial Progress | Phase 3 (2014-09-01) |
| Vendors | 72 |
Recent Clinical Trials for Tegafur
| Title | Sponsor | Phase |
|---|---|---|
| Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma | Sun Yat-sen University | Phase 2 |
| Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2/Phase 3 |
| A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Canc | Ono Pharmaceutical Co. Ltd | Phase 3 |
Clinical Trial Summary for Tegafur
Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur
US Patents for Tegafur
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tegafur | ⤷ Try it Free | Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same | Protalix Ltd. (Carmiel, IL) | ⤷ Try it Free |
| Tegafur | ⤷ Try it Free | Nuclear targeting sequences | Yeda Research and Development Co. Ltd. (Rehovot, IL) | ⤷ Try it Free |
| Tegafur | ⤷ Try it Free | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | ⤷ Try it Free |
| Tegafur | ⤷ Try it Free | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | ⤷ Try it Free |
| Tegafur | ⤷ Try it Free | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance | Evogene Ltd. (Rehovot, IL) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tegafur
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tegafur | European Patent Office | EP2134373 | 2027-02-28 | ⤷ Try it Free |
| Tegafur | European Patent Office | EP2839839 | 2027-02-28 | ⤷ Try it Free |
| Tegafur | Spain | ES2662036 | 2027-02-28 | ⤷ Try it Free |
| Tegafur | Israel | IL200578 | 2027-02-28 | ⤷ Try it Free |
| Tegafur | Israel | IL219783 | 2027-02-28 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
